T3 Thyroid Therapy: How to Select Liothyronine or NDT for Your Patient

What Is the T3 Drug Class and Why Does It Matter?

The T3 drug class encompasses all thyroid preparations that deliver the biologically active hormone triiodothyronine (T3) directly to the patient, either as the pure synthetic sodium salt (liothyronine) or as the partially purified porcine/bovine thyroid extract that contains both T4 and T3 (natural desiccated thyroid, NDT). Levothyroxine monotherapy normalizes TSH in most patients, but a clinically relevant subset continues to report fatigue, cognitive symptoms, and weight difficulty despite biochemically adequate T4 replacement. T3-containing regimens address the possibility that peripheral T4-to-T3 conversion is insufficient in those patients.

The Physiological Basis for T3 Therapy

Roughly 80% of circulating T3 is produced by peripheral deiodination of T4, primarily via type 1 and type 2 iodothyronine deiodinase (DIO1, DIO2). A common single-nucleotide polymorphism in DIO2, the Thr92Ala variant, reduces enzymatic activity in specific tissues and is present in approximately 15% of the population. A randomized crossover trial by Appelhof et al. (N=141) found that patients carrying the DIO2 Thr92Ala polymorphism reported significantly greater psychological well-being on combination T4/T3 therapy than on T4 alone (P<0.05) [1]. This is the mechanistic rationale for offering T3-containing agents to symptomatic patients despite normal TSH on levothyroxine.

Class Members at a Glance

The three prescribable T3 strategies are:

1. Liothyronine monotherapy (Cytomel 5 mcg, 25 mcg, 50 mcg tablets; generic equivalent). Pure synthetic T3. Used most often as an adjunct when added to levothyroxine, or as monotherapy in patients with thyroid cancer requiring T4 withdrawal before radioiodine scanning.
2. Natural desiccated thyroid (NDT) (Armour Thyroid, NP Thyroid, WP Thyroid, Nature-Throid). Standardized porcine thyroid extract containing both T4 and T3 at a fixed ratio of approximately 4:1 by weight. Armour 60 mg (1 grain) delivers 38 mcg T4 and 9 mcg T3.
3. Combination levothyroxine plus liothyronine dosed separately. This gives the prescriber independent control over T4 and T3 doses, which NDT does not allow because the 4:1 ratio is fixed.

Pharmacokinetics: Why T3's Short Half-Life Matters Clinically

Liothyronine has a plasma half-life of approximately 8 hours. Levothyroxine's half-life is approximately 7 days. This difference is the single most important pharmacokinetic fact governing T3 prescribing.

Peak-and-Trough Problem

A single daily liothyronine dose produces a supraphysiologic T3 spike within 2 to 4 hours, followed by a trough before the next dose. The spike can cause palpitations, tremor, and anxiety even when the 24-hour average T3 level is within range. Twice-daily dosing reduces peak-to-trough amplitude by roughly 40% compared with once-daily dosing in pharmacokinetic modeling studies [2].

Sustained-Release Liothyronine

A slow-release liothyronine preparation (LT3-SR) has been studied in several small trials. In a 12-week crossover trial published in the Journal of Clinical Endocrinology and Metabolism (N=23), Idrees et al. Found that LT3-SR produced smaller T3 excursions and higher patient-rated quality of life scores compared with immediate-release liothyronine, without a difference in TSH suppression [3]. This formulation is available compounded in the United States but does not carry FDA approval as a finished dosage form.

NDT Absorption vs. Liothyronine

NDT tablets contain both levothyroxine and liothyronine bound in thyroglobulin peptides. Digestion releases them at different rates. The T3 component still peaks within 2 to 4 hours post-dose, but because each tablet delivers a mixture of T4 and T3, the overall hormonal profile is smoother than pure liothyronine at equivalent T3 doses. The T4 fraction buffers the inter-dose trough by continuing to convert peripherally to T3 throughout the day.

Selecting the Right Agent: A Clinical Decision Framework

The choice among liothyronine, NDT, and combination therapy depends on five variables assessed at the initial prescription decision point.

Variable 1. Reason for T3 Consideration

| Clinical Scenario | Preferred Agent | |---|---| | Persistent symptoms despite optimal LT4, normal TSH | Combination LT4 + LT3 (separately dosed) or NDT | | Thyroid cancer: pre-RAI T4 withdrawal scan preparation | Liothyronine monotherapy (short-term, 2 to 4 weeks) | | Patient preference for "natural" preparation, no CV risk | NDT (Armour, NP Thyroid) | | Need for precise T3 titration independent of T4 | Separate LT4 + LT3 combination | | Myxedema coma IV rescue | IV liothyronine (Triostat) only |

Variable 2. Cardiovascular Risk

T3 excess increases heart rate and myocardial oxygen demand. The Copenhagen General Population Study (N=586,460) found that even mildly suppressed TSH (<0.4 mIU/L) was associated with a hazard ratio of 1.41 for atrial fibrillation (95% CI 1.27 to 1.56) [4]. Before starting any T3-containing regimen, screen for:

• Prior atrial fibrillation or flutter
• Ischemic heart disease or heart failure
• Hypertension with LVH
• Age above 60 years

Patients with any of these risk factors should have TSH maintained at the low-normal range (0.5 to 1.5 mIU/L) rather than fully suppressed, and free T3 must be checked 4 to 6 weeks after each dose change.

Variable 3. DIO2 Polymorphism Status

Genetic testing for DIO2 Thr92Ala is commercially available (most major labs, CPT 81479) but is not yet standard of care. The 2019 American Thyroid Association task force statement on combination therapy acknowledged the DIO2 data and stated, "Genetic characterization of patients is not routinely recommended but may inform individualized therapy in the future." [5] In practice, the phenotypic proxy (persistent symptoms plus low-normal free T3 despite mid-range TSH on levothyroxine) is sufficient to trigger a trial.

Variable 4. NDT vs. Separate Combination: The Ratio Problem

NDT's fixed 4:1 T4:T3 ratio by weight translates to a T4:T3 ratio of approximately 4.2:1 on a molar basis. Human thyroid gland secretion delivers a T4:T3 molar ratio closer to 14:1 to 20:1. This means every grain of NDT delivers substantially more T3, relative to T4, than a healthy human thyroid produces. Patients on NDT often run free T3 values in the upper third of the reference range and free T4 values in the lower third. For most otherwise healthy patients this is acceptable. For patients with cardiovascular disease or osteoporosis, the T3 excess from NDT may be more problematic than the independently controlled combination approach.

Variable 5. Patient Adherence and Practical Concerns

NDT requires consistent twice-daily dosing for most patients to avoid large inter-dose T3 swings. Liothyronine added to levothyroxine adds a second pill. Patients who already struggle with single-pill adherence to levothyroxine may do better with NDT, which consolidates both hormones into one tablet despite the fixed ratio trade-off.

Dosing Liothyronine: Starting Points and Titration

Liothyronine dosing requires more active monitoring than levothyroxine because TSH alone is insufficient to guide dose adjustments.

Starting Dose When Adding to Levothyroxine

The standard approach is to reduce the current levothyroxine dose by 25 to 50 mcg and add liothyronine 5 mcg twice daily. After 6 weeks, check TSH, free T4, and free T3. Target free T3 within the reference range (approximately 2.3 to 4.2 pg/mL in most assays). If symptoms persist and free T3 is <3.0 pg/mL with TSH still within range, increase liothyronine by 2.5 to 5 mcg per dose.

Ceiling and Safety Limits

The maximum liothyronine dose in combination regimens is not formally codified in FDA labeling, but most endocrine clinical practice keeps total daily liothyronine at or below 20 to 25 mcg/day unless monotherapy is being used in a cancer withdrawal protocol. Exceeding this threshold without monitoring free T3 produces a meaningful risk of biochemical thyrotoxicosis.

Liothyronine Monotherapy for Hypothyroidism

Liothyronine monotherapy for routine hypothyroidism is uncommon and generally not recommended by the 2012 American Thyroid Association guidelines [6]. The half-life limitation means TSH is an unreliable endpoint; TSH may be suppressed when the 24-hour mean T3 is actually in range. Free T3 checked at the trough (just before the morning dose) is the most clinically meaningful lab value in this setting.

Dosing NDT: Grains, Milligrams, and Conversion Math

Grain-Based Dosing

NDT is dosed in grains (1 grain = 60 mg for Armour Thyroid, but 65 mg for some other brands). Common starting grain strengths are 0.5 grain, 1 grain, 1.5 grains, 2 grains, and 3 grains. Armour Thyroid 1 grain contains 38 mcg levothyroxine equivalent and 9 mcg liothyronine equivalent. The liothyronine portion contributes disproportionately to metabolic effect because T3 is 3 to 4 times more potent than T4 at receptor level.

Converting from Levothyroxine to NDT

A practical conversion is that 100 mcg levothyroxine approximates 1 grain (60 mg) of Armour Thyroid. This is an approximation only. Given the higher T3 load, patients switching from levothyroxine should start NDT at a dose slightly below the calculated equivalent and titrate up over 6 to 8 weeks, checking TSH, free T4, and free T3 at each interval.

Twice-Daily NDT Dosing

Some clinicians split the total daily NDT dose into two-thirds in the morning and one-third at midday to flatten T3 peaks. A small randomized study by Hoang et al. (N=70) published in the Journal of Clinical Endocrinology and Metabolism found that patients randomized to NDT rather than levothyroxine reported statistically significant improvements in body weight and quality-of-life scores, though thyroid function values were equivalent [7]. Twice-daily dosing was used in that protocol.

Guideline Field and Where T3 Therapy Currently Stands

2012 ATA/ETA Guidelines

The joint American Thyroid Association and European Thyroid Association 2012 guidelines on hypothyroidism state that levothyroxine monotherapy remains the standard of care for most patients [6]. They acknowledge that combination T4/T3 therapy "cannot be recommended for routine use" but note that a subset of patients may benefit.

2019 ATA Task Force on Combination Therapy

A dedicated ATA task force reviewed the evidence base for combination therapy in 2019. The task force concluded, "A trial of combination LT4/LT3 therapy might be considered in patients with hypothyroidism who have persistent symptoms despite optimal LT4 therapy, after other causes of symptoms have been excluded." [5] This language represents a modest but real shift toward endorsing T3 therapy in selected patients.

European Thyroid Association 2021 Guidelines

The 2021 ETA guidelines on hypothyroidism similarly state that combination therapy is "an option in patients who do not feel well on LT4 alone" and recommend free T3 monitoring to prevent over-replacement [8]. They specifically advise against NDT as first-line because of the supra-physiological T3:T4 ratio.

Monitoring Protocol for T3-Containing Regimens

Monitoring T3-containing regimens is more intensive than monitoring levothyroxine monotherapy because TSH alone does not capture T3 excess.

Lab Panel at Each Titration Visit

• TSH (target: 0.5 to 2.5 mIU/L for most patients; 0.1 to 0.5 mIU/L for differentiated thyroid cancer per ATA risk stratification)
• Free T4
• Free T3 (check at trough: before first morning dose, or 12 hours after last NDT dose)
• Heart rate and rhythm assessment at each visit
• Annual bone density baseline in postmenopausal women or patients with osteoporosis risk

Timing of Labs

Check first follow-up panel 6 weeks after any dose change. Once stable, annual monitoring is appropriate provided the patient is asymptomatic.

Red Flags Requiring Immediate Dose Reduction

• Resting heart rate above 90 beats per minute
• New palpitations, tremor, or heat intolerance
• Free T3 above the upper limit of the reference range on any single measurement
• TSH <0.1 mIU/L in a patient without thyroid cancer

Special Populations

Thyroid Cancer Patients

Liothyronine monotherapy is used to stimulate TSH before radioiodine remnant ablation or diagnostic scanning in patients who cannot receive recombinant TSH (Thyrogen). The standard protocol is levothyroxine withdrawal over 4 weeks followed by liothyronine 25 mcg twice daily for 2 weeks, then liothyronine discontinuation for 2 weeks to allow TSH to rise above 30 mIU/L before radioiodine administration. This protocol is detailed in ATA 2015 differentiated thyroid cancer management guidelines [9].

Pregnancy

T3-containing regimens are generally avoided in pregnancy. Levothyroxine is the only recommended thyroid replacement during pregnancy per both the 2017 ATA guidelines on thyroid disease in pregnancy and ACOG Committee Opinion 97 [10, 11]. Liothyronine crosses the placenta poorly and does not reliably supply fetal thyroid needs. Women on combination therapy or NDT who become pregnant should be transitioned to levothyroxine only.

Elderly Patients

Patients over 65 years have higher sensitivity to T3 excess. The American Geriatrics Society recommends conservative TSH targets (1.0 to 3.0 mIU/L) in older adults [12]. T3-containing regimens in this population require more frequent monitoring and should be initiated at the lowest available dose (liothyronine 2.5 mcg daily if necessary, using a pill cutter or compounded preparation).

NDT Supply and Regulatory Considerations

Armour Thyroid (AbbVie) and NP Thyroid (Acella) are the two commercially dominant NDT brands in the United States. Both have experienced intermittent supply disruptions in recent years. WP Thyroid and Nature-Throid (RLC Labs) underwent FDA manufacturing compliance actions in 2020 and availability has been inconsistent since [13].

The FDA classifies NDT products as "generally recognized as safe and effective" (GRAS/GRAE) under the ongoing Unified Agenda rulemaking process. They are not required to have gone through the standard NDA pathway that liothyronine sodium (Cytomel) completed. Clinicians should counsel patients that NDT formulations can vary slightly in potency between manufacturing lots, and TSH should be re-checked if a patient switches brands or if the brand resumes production after a supply disruption.